» Articles » PMID: 34599235

A Vascularized Tumoroid Model for Human Glioblastoma Angiogenesis

Overview
Journal Sci Rep
Specialty Science
Date 2021 Oct 2
PMID 34599235
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Glioblastoma (GBM) angiogenesis is critical for tumor growth and recurrence, making it a compelling therapeutic target. Here, a disease-relevant, vascularized tumoroid in vitro model with stem-like features and stromal surrounds is reported. The model is used to recapitulate how individual components of the GBM's complex brain microenvironment such as hypoxia, vasculature-related stromal cells and growth factors support GBM angiogenesis. It is scalable, tractable, cost-effective and can be used with biologically-derived or biomimetic matrices. Patient-derived primary GBM cells are found to closely participate in blood vessel formation in contrast to a GBM cell line containing differentiated cells. Exogenous growth factors amplify this effect under normoxia but not at hypoxia suggesting that a significant amount of growth factors is already being produced under hypoxic conditions. Under hypoxia, primary GBM cells strongly co-localize with umbilical vein endothelial cells to form sprouting vascular networks, which has been reported to occur in vivo. These findings demonstrate that our 3D tumoroid in vitro model exhibits biomimetic attributes that may permit its use as a preclinical model in studying microenvironment cues of tumor angiogenesis.

Citing Articles

Personalising glioblastoma medicine: explant organoid applications, challenges and future perspectives.

Skarne N, DSouza R, Palethorpe H, Bradbrook K, Gomez G, Day B Acta Neuropathol Commun. 2025; 13(1):6.

PMID: 39799339 PMC: 11724554. DOI: 10.1186/s40478-025-01928-x.


Practical immunomodulatory landscape of glioblastoma multiforme (GBM) therapy.

Norollahi S, Yousefi B, Nejatifar F, Yousefzadeh-Chabok S, Rashidy-Pour A, Samadani A J Egypt Natl Canc Inst. 2024; 36(1):33.

PMID: 39465481 DOI: 10.1186/s43046-024-00240-4.


Tumoroids, a valid preclinical screening platform for monitoring cancer angiogenesis.

Abbasi-Malati Z, Khanicheragh P, Narmi M, Mardi N, Khosrowshahi N, Hiradfar A Stem Cell Res Ther. 2024; 15(1):267.

PMID: 39183337 PMC: 11346257. DOI: 10.1186/s13287-024-03880-4.


The role of postoperative blood pressure management in early postoperative hemorrhage in awake craniotomy glioma patients.

Demetz M, Krigers A, Uribe-Pacheco R, Pinggera D, Klingenschmid J, Thome C Neurosurg Rev. 2024; 47(1):452.

PMID: 39168945 PMC: 11339099. DOI: 10.1007/s10143-024-02661-0.


Recurrent Glioblastoma-Molecular Underpinnings and Evolving Treatment Paradigms.

Chang C, Chavarro V, Gerstl J, Blitz S, Spanehl L, Dubinski D Int J Mol Sci. 2024; 25(12).

PMID: 38928445 PMC: 11203521. DOI: 10.3390/ijms25126733.


References
1.
Souberan A, Tchoghandjian A . Practical Review on Preclinical Human Glioblastoma Models: Advances and Challenges for Clinical Translation. Cancers (Basel). 2020; 12(9). PMC: 7563542. DOI: 10.3390/cancers12092347. View

2.
Chen J, Li Y, Yu T, McKay R, Burns D, Kernie S . A restricted cell population propagates glioblastoma growth after chemotherapy. Nature. 2012; 488(7412):522-6. PMC: 3427400. DOI: 10.1038/nature11287. View

3.
Rezk R, Jia B, Wendler A, Dimov I, Watts C, Markaki A . Spatial heterogeneity of cell-matrix adhesive forces predicts human glioblastoma migration. Neurooncol Adv. 2020; 2(1):vdaa081. PMC: 7415261. DOI: 10.1093/noajnl/vdaa081. View

4.
Krcek R, Matschke V, Theis V, Adamietz I, Buhler H, Theiss C . Vascular Endothelial Growth Factor, Irradiation, and Axitinib Have Diverse Effects on Motility and Proliferation of Glioblastoma Multiforme Cells. Front Oncol. 2017; 7:182. PMC: 5572260. DOI: 10.3389/fonc.2017.00182. View

5.
Gabriely G, Wheeler M, Takenaka M, Quintana F . Role of AHR and HIF-1α in Glioblastoma Metabolism. Trends Endocrinol Metab. 2017; 28(6):428-436. PMC: 5438779. DOI: 10.1016/j.tem.2017.02.009. View